Related Experiment Videos
CA 125: a useful marker in endometrial carcinoma
American Journal of Obstetrics and Gynecology
|November 1, 1986
Summary
CA 125 is present in all endometrial cancer tissues, but elevated serum levels are uncommon in early stages. Higher stages and vessel invasion correlate with increased CA 125, indicating its potential as a biomarker for disease progression and recurrence.
Area of Science:
- Oncology
- Gynecologic Oncology
- Biomarkers
Background:
- CA 125 is a tumor-associated antigen.
- Its role as a biomarker in endometrial cancer requires further elucidation.
Purpose of the Study:
- To investigate the presence of CA 125 in endometrial cancer tissues.
- To evaluate the correlation between serum CA 125 levels and clinicopathological features of endometrial cancer.
- To assess the utility of serum CA 125 as a prognostic marker.
Main Methods:
- Retrospective analysis of 121 endometrial cancer patients.
- Immunohistochemical testing of 20 primary endometrial adenocarcinomas for CA 125.
- Measurement of serum CA 125 levels before treatment.
- Correlation of serum CA 125 with tumor stage, histopathology, and clinical course.
Main Results:
- CA 125 was detected in all tested endometrial tumor tissues.
- Only 25% of patients had elevated serum CA 125 pre-treatment.
- Elevated serum CA 125 levels significantly correlated with advanced International Federation of Gynecology and Obstetrics (FIGO) stages (III and IV), presence of extrauterine disease, and vessel invasion.
- Serum CA 125 levels demonstrated a parallel course with the clinical disease and could precede abdominal recurrence.
Conclusions:
- CA 125 is ubiquitously expressed in endometrial cancer tissues.
- Serum CA 125 is a valuable biomarker for advanced disease, indicating poor prognostic factors.
- Monitoring serum CA 125 may aid in detecting recurrence and guiding clinical management of endometrial cancer.